Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women

Davis, Susan Ruth; Stuckey, Bronwyn; Norman, Robert J.; Papalia, Mary-Anne; Drillich, Ann Dorothy; Bell, Robin Jean

doi:10.1097/gme.0b013e318174f16e

Cited by 8 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oral, but not transdermal, oestrogen therapy suppresses serum IGF-1 levels [60]. In addition, acidosis has been shown to reduce IGF-1 levels [27].…”

Section: Igf-1 From Bench To Bedside and Beyondmentioning

confidence: 99%

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

et al. 2011

View full text Add to dashboard Cite

IGF-1 (insulin-like growth factor-1) plays a unique role in the cell protection of multiple systems, where its fine-tuned signal transduction helps to preserve tissues from hypoxia, ischaemia and oxidative stress, thus mediating functional homoeostatic adjustments. In contrast, its deprivation results in apoptosis and dysfunction. Many prospective epidemiological surveys have associated low IGF-1 levels with late mortality, MI (myocardial infarction), HF (heart failure) and diabetes. Interventional studies suggest that IGF-1 has anti-atherogenic actions, owing to its multifaceted impact on cardiovascular risk factors and diseases. The metabolic ability of IGF-1 in coupling vasodilation with improved function plays a key role in these actions. The endothelial-protective, anti-platelet and anti-thrombotic activities of IGF-1 exert critical effects in preventing both vascular damage and mechanisms that lead to unstable coronary plaques and syndromes. The pro-survival and anti-inflammatory short-term properties of IGF-1 appear to reduce infarct size and improve LV (left ventricular) remodelling after MI. An immune-modulatory ability, which is able to suppress 'friendly fire' and autoreactivity, is a proposed important additional mechanism explaining the anti-thrombotic and anti-remodelling activities of IGF-1. The concern of cancer risk raised by long-term therapy with IGF-1, however, deserves further study. In the present review, we discuss the large body of published evidence and review data on rhIGF-1 (recombinant human IGF-1) administration in cardiovascular disease and diabetes, with a focus on dosage and safety issues. Perhaps the time has come for the regenerative properties of IGF-1 to be assessed as a new pharmacological tool in cardiovascular medicine.

show abstract

“…Oral, but not transdermal, oestrogen therapy suppresses serum IGF-1 levels [60]. In addition, acidosis has been shown to reduce IGF-1 levels [27].…”

Section: Igf-1 From Bench To Bedside and Beyondmentioning

confidence: 99%

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A later large randomized controlled trial comparing three different doses of transdermal testosterone with placebo found that there was an increase in the frequency of the number of satisfactory sexual events in women treated with the middle dose of testosterone compared to placebo [35]. A Cochran review of TTh in postmenopausal women for low libido concluded that there are benefits in terms of improved sexual function with the addition of testosterone to standard postmenopausal hormone therapy [36].…”

Section: Tth Studiesmentioning

confidence: 99%

Testosterone Therapy for Female Sexual Dysfunction

Khera

2015

Sexual Medicine Reviews

View full text Add to dashboard Cite

“…Although the cortisol-related rise in IGF-I that we observed has also been reported by others in response to exogenous glucocorticoid administration (Borges, et al, 1999) and in conditions of chronic hypercortisolemia such as Cushing’s syndrome (Bang, et al, 1993) or depression (Weber-Hamann, et al, 2009), the modulating effect of estradiol on the IGF-1 response to cortisol has not been previously described. This interactive effect of estradiol and cortisol may account, at least in part, for discrepant reports in the literature regarding estradiol effects on IGF-I although the impact of other variables such as dose and route of delivery also need to be weighed (Davis, et al, 2008). …”

Section: Discussionmentioning

confidence: 99%

Cognitive response to estradiol in postmenopausal women is modified by high cortisol

Baker¹,

Asthana²,

Cholerton³

et al. 2012

Neurobiology of Aging

View full text Add to dashboard Cite

Estradiol has potent favorable effects on brain function and behavior in animals while in human trials, the results are inconsistent. A number of potential mediating variables influencing response to estradiol have been proposed to account for this variability, one of which includes stress. We conducted a placebo-controlled study to examine joint and independent effects of estradiol and elevated levels of the stress hormone cortisol on cognition and biomarkers of aging and neurodegenerative disease. Thirty-nine healthy postmenopausal women (56-84 yrs) received 0.10 mg/d of transdermal 17β-estradiol (E2) or placebo for eight weeks. During the last four days of the trial, subjects also received 90 mg/d (30 mg TID) of oral hydrocortisone (CORT) to induce stress-level elevations in cortisol, or a matched placebo. The four groups thus included Placebo (placebo patch/placebo pill), CORT-alone (placebo patch/hydrocortisone), E2-alone (estradiol patch/placebo pill), and E2+CORT (estradiol patch/hydrocortisone). Eight weeks of E2 increased plasma estradiol by 167%, and four days of CORT increased plasma cortisol by 119%. Overall, E2 had favorable effects on verbal memory (p=0.03), working memory (p=0.02), and selective attention (p=0.04), and the magnitude of these effects was attenuated for E2+CORT. E2-alone and E2+CORT had opposing effects on plasma levels of the amyloid-β (Aβ) biomarker (Aβ40/42 ratio, p<0.05), with the more favorable response observed for E2-alone. CORT-induced increases in insulin-like growth factor-1 were blunted by E2 co-administration. Our findings indicate that cognitive and physiological responses to estradiol are adversely affected by elevated stress hormone levels of cortisol in healthy postmenopausal women.

show abstract

Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women

Cited by 8 publications

References 27 publications

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

IGF-1 and atherothrombosis: relevance to pathophysiology and therapy

Testosterone Therapy for Female Sexual Dysfunction

Cognitive response to estradiol in postmenopausal women is modified by high cortisol

Contact Info

Product

Resources

About